We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Organon (OGN - Free Report) closed the most recent trading day at $8.60, moving -5.91% from the previous trading session. This change lagged the S&P 500's 0.41% loss on the day. Meanwhile, the Dow lost 0.36%, and the Nasdaq, a tech-heavy index, lost 0.89%.
Coming into today, shares of the pharmaceutical company had gained 49.84% in the past month. In that same time, the Medical sector gained 0.47%, while the S&P 500 gained 9.71%.
The upcoming earnings release of Organon will be of great interest to investors. The company's earnings report is expected on May 7, 2026. The company is predicted to post an EPS of $0.84, indicating a 17.65% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $1.47 billion, reflecting a 3.12% fall from the equivalent quarter last year.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.38 per share and revenue of $6.17 billion. These results would represent year-over-year changes of -7.65% and -0.76%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Organon. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.1% upward. Organon is holding a Zacks Rank of #3 (Hold) right now.
Looking at valuation, Organon is presently trading at a Forward P/E ratio of 2.71. This represents a discount compared to its industry average Forward P/E of 16.14.
We can also see that OGN currently has a PEG ratio of 0.81. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical Services industry stood at 1.41 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 78, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Organon (OGN) Dips More Than Broader Market: What You Should Know
Organon (OGN - Free Report) closed the most recent trading day at $8.60, moving -5.91% from the previous trading session. This change lagged the S&P 500's 0.41% loss on the day. Meanwhile, the Dow lost 0.36%, and the Nasdaq, a tech-heavy index, lost 0.89%.
Coming into today, shares of the pharmaceutical company had gained 49.84% in the past month. In that same time, the Medical sector gained 0.47%, while the S&P 500 gained 9.71%.
The upcoming earnings release of Organon will be of great interest to investors. The company's earnings report is expected on May 7, 2026. The company is predicted to post an EPS of $0.84, indicating a 17.65% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $1.47 billion, reflecting a 3.12% fall from the equivalent quarter last year.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.38 per share and revenue of $6.17 billion. These results would represent year-over-year changes of -7.65% and -0.76%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Organon. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.1% upward. Organon is holding a Zacks Rank of #3 (Hold) right now.
Looking at valuation, Organon is presently trading at a Forward P/E ratio of 2.71. This represents a discount compared to its industry average Forward P/E of 16.14.
We can also see that OGN currently has a PEG ratio of 0.81. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical Services industry stood at 1.41 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 78, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.